Phase 2 study of aldoxorubicin in relapsed glioblastoma.

被引：5
|
作者：
Groves, Morris D.
Portnow, Jana
Boulmay, Brian C.
Chawla, Sant P.
Dinh, Hillary
Chawla, Shanta
Wieland, Scott
Levitt, Daniel J.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.2027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2027
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase 2 Study of Aldoxorubicin versus Topotecan for Relapsed/Refractory Small Cell Lung Cancer
    Chawla, Shanta
    Wieland, Scott
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S742 - S742
  • [2] PHASE 2 STUDY OF ALDOXORUBICIN VERSUS TOPETECAN FOR RELAPSED/REFRACTORY SMALL CELL LUNG CANCER
    Wieland, S.
    Mita, A.
    Piantadosi, S.
    Natale, R.
    Levitt, D.
    ANNALS OF ONCOLOGY, 2014, 25
  • [3] Phase II study of bevacizumab and vorinostat for recurrent glioblastoma.
    Ghiaseddin, Ashley
    Reardon, David A.
    Massey, Woody
    Mannerino, Alexandra
    Lipp, Eric S.
    Herndon, James E.
    McSherry, Frances
    Desjardins, Annick
    Randazzo, Dina M.
    Vlahovic, Gordana
    Friedman, Henry S.
    Peters, Katherine B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma.
    Kelly, Andrea True
    Ambady, Prakash
    Brown, Michael
    Butowski, Nicholas
    Cavaliere, Robert
    Curry, William
    Desjardins, Annick
    Franklin, Lisa
    Friedman, Henry
    Gromeier, Matthias
    Jackson, Leann
    Mixson, Lori
    Ong, Shirley
    Randazzo, Dina
    Sloan, Andrew
    Wen, Patrick
    Nichols., Garrett
    CANCER RESEARCH, 2021, 81 (13)
  • [5] LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma.
    Sloan, Andrew E.
    Buerki, Robin Arthur
    Murphy, Christopher
    Kelly, Andrea True
    Ambady, Prakash
    Brown, Michael
    Butowski, Nicholas A.
    Cavaliere, Robert
    Curry, William T.
    Desjardins, Annick
    Franklin, Lisa
    Friedman, Henry S.
    Gromeier, Matthias
    Jackson, Leann
    Mixson, Lori
    Ong, Shirley S.
    Randazzo, Dina
    Wen, Patrick Y.
    Nichols, Garrett
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] A phase 0/II study for ribicoclib in patients with recurrent glioblastoma.
    Sanai, Nader
    Tien, An-Chi
    Honea, Norissa
    Mehta, Shwetal
    Li, Jing
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Phase II study of dose-intense temozolomide in recurrent glioblastoma.
    Hammond, S.
    Norden, A. D.
    Lesser, G. J.
    Drappatz, J.
    Fadul, C. E.
    Batchelor, T.
    Quant, E. C.
    Beroukhim, R.
    Muzikansky, A.
    Ciampa, A. S.
    Doherty, L. M.
    LaFrankie, D. C.
    Ruland, S.
    Bochacki, C. A.
    Griffin, K.
    Gerard, M.
    Sceppa, C.
    Rosenfeld, M. R.
    Wen, P. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma.
    Altwairgi, Abdullah Khalaf
    Alghareeb, Waleed Ali
    AlNajjar, Fouad H.
    Mubasher, Mohammed
    Alhussain, Hussain
    Saleh, Rasha Mustafa
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [9] Phase II trial of dovitinib in recurrent glioblastoma.
    Ahluwalia, Manmeet Singh
    Papadantonakis, Nikolaos
    Venur, Vyshak Alva
    Schilero, Cathy
    Peereboom, David M.
    Stevens, Glen
    Rosenfeld, Steven
    Vogelbaum, Michael A.
    Elson, Paul
    Nixon, Andrew B.
    McCrae, Keith
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] A phase II, multicenter, prospective study of sacituzumab govitecan in recurrent glioblastoma.
    Kelly, William
    Cordova, Christine
    Vaillant, Brian D.
    Balinda, Henriette
    Michalek, Joel
    Gilbert, Andrea
    Floyd, John
    Brenner, Andrew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345